Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
634 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02702414 | Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224) | completed | Phase 2 | 156 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 4, 2024 | clinicaltrials |
| NCT01284348 | To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Participants With Advanced Non-small Cell Lung Cancer | terminated | Phase 2 | 26 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 29, 2024 |
| clinicaltrials |
| NCT03473925 | Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034) | completed | Phase 2 | 107 | Merck Sharp & Dohme LLCINDUSTRY | 5 | Aug 28, 2024 | clinicaltrials |
| NCT03284424 | Study of Pembrolizumab (MK-3475) in Adults With Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) or Locally Advanced Unresectable cSCC (MK-3475-629/KEYNOTE-629) | completed | Phase 2 | 159 | Merck Sharp & Dohme LLCINDUSTRY | 10 | Aug 23, 2024 | clinicaltrials |
| NCT03664024 | Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782)(KEYNOTE-782) | completed | Phase 2 | 118 | Merck Sharp & Dohme LLCINDUSTRY | 5 | Aug 22, 2024 | clinicaltrials |
| NCT04152863 | Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011) | terminated | Phase 2 | 85 | Merck Sharp & Dohme LLCINDUSTRY | 11 | Aug 6, 2024 | clinicaltrials |
| NCT04907227 | Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China Extension | terminated | Phase 3 | 81 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Jul 12, 2024 | clinicaltrials |
| NCT03382600 | Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With TS-1+Cisplatin or TS-1+Oxaliplatin as First Line Chemotherapy in Gastric Cancer (MK-3475-659/KEYNOTE-659) | completed | Phase 2 | 100 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Jun 11, 2024 | clinicaltrials |
| NCT03950674 | Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study | completed | Phase 3 | 40 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Jun 10, 2024 | clinicaltrials |
| NCT00543387 | Treatment of Participants With Advanced and/or Refractory Solid Tumors (MK-5108-001) | completed | Phase 1 | 35 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 5, 2024 | clinicaltrials |
| NCT00963547 | A Study of MK-2206 in Combination With Trastuzumab and Lapatinib for the Treatment of HER2+ Solid Tumors (MK-2206-015) | terminated | Phase 1 | 33 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 4, 2024 | clinicaltrials |
| NCT02821000 | Safety and Efficacy Study of Pembrolizumab (MK-3475) in Chinese Participants With Locally Advanced or Metastatic Melanoma (MK-3475-151/KEYNOTE-151) | completed | Phase 1 | 103 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 30, 2024 | clinicaltrials |
| NCT00694083 | Study of Ridaforolimus (MK-8669) in Participants With Solid Tumors (MK-8669-003)(COMPLETED) | completed | Phase 1 | 13 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 21, 2024 | clinicaltrials |
| NCT01190644 | Study to Evaluate Effect of a Single Dose of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Participants With Solid Tumors | terminated | Phase 2 | 5 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Nov 29, 2023 | clinicaltrials |
| NCT02054806 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28) | completed | Phase 1 | 477 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Oct 30, 2023 | clinicaltrials |
| NCT03302234 | Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598) | completed | Phase 3 | 568 | Merck Sharp & Dohme LLCINDUSTRY | 24 | Sep 26, 2023 | clinicaltrials |
| NCT00648648 | A Dose Escalation Study of Adavosertib (MK-1775) in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors (MK-1775-001) | completed | Phase 1 | 206 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 21, 2023 | clinicaltrials |
| NCT01047007 | A Dose Escalation Study of Adavosertib(MK1775) in Combination With 5-FU or 5-FU/CDDP in Patients With Advanced Solid Tumor (1775-005 | terminated | Phase 1 | 11 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 21, 2023 | clinicaltrials |
| NCT01357161 | A Study of Adavosertib (MK-1775) in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004) | completed | Phase 2 | 136 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 21, 2023 | clinicaltrials |
| NCT01076400 | A Study of Adavosertib (MK-1775) in Combination With Topotecan/Cisplatin in Participants With Cervical Cancer (MK-1775-008) | terminated | Phase 1 / Phase 2 | 7 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 18, 2023 | clinicaltrials |
| NCT00931606 | Study of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer (MK-7962-012) | terminated | Phase 2 | 30 | Merck Sharp & Dohme LLCINDUSTRY | 2 | Sep 13, 2023 | clinicaltrials |
| NCT02853305 | Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361) | completed | Phase 3 | 1,010 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 8, 2023 | clinicaltrials |
| NCT02460198 | Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164) | completed | Phase 2 | 124 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jul 27, 2023 | clinicaltrials |
| NCT02576990 | Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170) | completed | Phase 2 | 80 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jul 27, 2023 | clinicaltrials |
| NCT03745989 | Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014) | completed | Phase 1 | 30 | Merck Sharp & Dohme LLCINDUSTRY | 3 | Jul 27, 2023 | clinicaltrials |
| NCT02252042 | Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040) | completed | Phase 3 | 495 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jul 17, 2023 | clinicaltrials |
| NCT02611960 | Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122/KEYNOTE-122) | completed | Phase 3 | 233 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jul 13, 2023 | clinicaltrials |
| NCT00380367 | Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029) | completed | Phase 3 | 110 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 31, 2023 | clinicaltrials |
| NCT02761694 | Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations (MK-4440-001) | terminated | Phase 1 | 78 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 1 | May 6, 2023 | clinicaltrials |
| NCT02494583 | Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062) | completed | Phase 3 | 763 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 13, 2023 | clinicaltrials |
| NCT02853344 | Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427) | completed | Phase 2 | 275 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 11, 2023 | clinicaltrials |
| NCT02564263 | Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181) | completed | Phase 3 | 628 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 13, 2023 | clinicaltrials |
| NCT02335424 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-052) | completed | Phase 2 | 374 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 2, 2023 | clinicaltrials |
| NCT05314023 | Immunogenicity and Safety of V503 in Chinese Males 9 Through 19 Years Old (V503-053) | active not recruiting | Phase 3 | 1,590 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Jan 19, 2023 | clinicaltrials |
| NCT02039674 | A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021) | completed | Phase 1 / Phase 2 | 267 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 8, 2022 | clinicaltrials |
| NCT02835690 | Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Pembrolizumab (MK-3475) in Chinese Participants With Non-Small-Cell Lung Cancer (MK-3475-032/KEYNOTE-032) | completed | Phase 1 | 44 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Oct 26, 2022 | clinicaltrials |
| NCT01736683 | Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML) | completed | Phase 2 | 74 | Merck Sharp & Dohme LLCINDUSTRY | 2 | Oct 24, 2022 | clinicaltrials |
| NCT00943722 | A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002) | completed | Phase 3 | 3,074 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Oct 3, 2022 | clinicaltrials |
| NCT03066778 | A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604) | completed | Phase 3 | 453 | Merck Sharp & Dohme LLCINDUSTRY | 19 | Oct 3, 2022 | clinicaltrials |
| NCT02702401 | Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240) | completed | Phase 3 | 413 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 29, 2022 | clinicaltrials |
| NCT00419367 | Compassionate Use of Vorinostat for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma (0683-042) | no longer available | — | — | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 22, 2022 | clinicaltrials |
| NCT02559687 | Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180) | completed | Phase 2 | 121 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 14, 2022 | clinicaltrials |
| NCT00127127 | A Study of Vorinostat in Patients With Solid Tumors (MK-0683-029) | completed | Phase 1 | 18 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 13, 2022 | clinicaltrials |
| NCT01077856 | GARDASIL™ Vaccine Impact in Population Study (V501-033)(VIP) | completed | — | 54,516 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 13, 2022 | clinicaltrials |
| NCT02089685 | Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29) | completed | Phase 1 / Phase 2 | 295 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 13, 2022 | clinicaltrials |
| NCT02698189 | A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Hematologic Malignancies (MK-8628-005) | terminated | Phase 1 | 9 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 13, 2022 | clinicaltrials |
| NCT05450705 | V503 in Chinese Girls 9-14 Years Old Versus Chinese Women 20-26 Years Old (V503-071) | active not recruiting | Phase 3 | 1,500 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Sep 2, 2022 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials